Skip to content

Lifestyle trial detected no quality-of-life advantage during breast cancer chemotherapy

A trial found no clear difference in quality-of-life changes between nutrition and exercise support and usual care during breast cancer chemotherapy.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

The program improved nutrition and exercise, but researchers detected no advantage over usual care in limiting quality-of-life declines during chemotherapy. Both groups reported worsening in several areas of well-being, while anxiety improved. These findings apply to the tested program and population; they do not establish equivalence or determine what other lifestyle programs might achieve.

Keep in mind

The abstract provides no between-group confidence intervals, making it difficult to judge what smaller effects remain possible. The absence of an observed difference is not proof that the approaches were equivalent.

THE RESULT, WITH CONTEXT

What researchers found

No between-group difference detected

PROMIS quality-of-life questionnaire outcomes

Nutrition and exercise versus usual care, from diagnosis to the postchemotherapy assessment.

JNCI Cancer Spectr, 2026 · Original source ↓

What the trial measured

Researchers randomly assigned women beginning chemotherapy to nutrition and exercise support or usual care. The questionnaires tracked multiple aspects of well-being, including physical function, fatigue, cognition, social roles and overall health.

Changes over follow-up

Most questionnaire scores returned to their starting levels by 1 year and stayed stable through 2 years. Anxiety improved by the postchemotherapy assessment and remained improved; the abstract reports no advantage for the intervention group.

CHECK THE ORIGINAL

The original publication

Effect of a lifestyle intervention during chemotherapy for breast cancer on quality of life.

Puklin LS, Li FY, Ferrucci LM et al.
JNCI Cancer Spectr · 2026

PubMed ID
41452765
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.